Atossa Genetics, Inc.
ATOS, The Breast Health Company(TM), will display its
ForeCYTE Breast Health Test at the 7th annual Breast Cancer Symposium
from September 7 through September 9, 2013 in San Francisco. Atossa's
exhibit will be located in Booth 33 at the San Francisco Marriott
Marquis -- Golden Gate Hall.
The ForeCYTE Breast Health Test, developed and marketed by Atossa's
subsidiary, The National Reference Laboratory for Breast Health,
detects reversible precancerous conditions in the breast up to eight
years before they become cancer. The test uses Atossa's hand-held,
FDA Class II medical device that is quick, painless, and non-invasive
and can be administered during an OB/GYN office visit. Unlike
mammograms, which are commonly recommended for women starting at age
40 to 50, the ForeCYTE Breast Health Test is more age agnostic, uses
no radiation and does not require invasive biopsy needles or surgical
incisions. To view a video about the ForeCYTE Test, click here:
https://vimeo.com/62365818.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in